SCHEMBL5682170

SCHEMBL5682170

Cc1nn([C@H](N)C(C)OC(=O)/C=C/C(=O)OC(C)[C@@H](N)n2nc(C)c3cc(F)c(F)cc32)c2cc(F)c(F)cc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5682007 0.91 PTGS2 (0.32)
SCHEMBL5678015 0.81 SMN1; SMN2 (0.46)
SCHEMBL5678098 0.81 DYRK1A (0.38)
SCHEMBL5678034 0.74 PTGDR2 (0.34)
SCHEMBL7778328 0.72 ADORA2A (0.34)
SCHEMBL905694 0.71 ADORA2A (0.33)
SCHEMBL5682015 0.70 SLC22A12 (0.32)
SCHEMBL7779507 0.70 SLC22A12 (0.32)
SCHEMBL5678114 0.70 DPP7 (0.34)
SCHEMBL7772318 0.70 NLRP3 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1129078-B1 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RES LTD (GB) 2006-03-15 EP disclosed
US-6552062-B1 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity VERNALIS RESEARCH LIMITED (GB) 2003-04-22 US disclosed